{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:00:34Z","timestamp":1793383234495,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2021YFA1100800"],"award-info":[{"award-number":["2021YFA1100800"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070168"],"award-info":[{"award-number":["82070168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830004"],"award-info":[{"award-number":["81830004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830006"],"award-info":[{"award-number":["81830006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2021C03117"],"award-info":[{"award-number":["2021C03117"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jcyt.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:24:30Z","timestamp":1669652670000},"page":"573-577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Xiuyong","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2022.10.010_bib0001","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0002","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0003","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0004","first-page":"20","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","author":"Locke","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0008","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006715","article-title":"Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR\/SD After CAR T-cell Therapy","author":"Al Zaki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0010","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy","author":"Shouval","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/science.1636093","article-title":"An eosinophil-dependent mechanism for the antitumor effect of interleukin-4","volume":"257","author":"Tepper","year":"1992","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2016.42","article-title":"Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study","volume":"29","author":"Prizment","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1727116","article-title":"Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors","volume":"9","author":"Simon","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0014","article-title":"Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1\/PD-L1 Checkpoint Inhibitors","author":"Mota","year":"2021","journal-title":"Journal of immunotherapy (Hagerstown, Md: 1997)"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/bjh.14705","article-title":"Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition","volume":"181","author":"Hude","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0016","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nature immunology"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0017","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.7150\/thno.54546","article-title":"Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma","volume":"11","author":"Jia","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0018","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.stemcr.2021.06.005","article-title":"Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors","volume":"16","author":"Lai","year":"2021","journal-title":"Stem cell reports"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0019","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0020","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2174\/0929867323666160119094313","article-title":"Eosinophils in Cancer: Favourable or Unfavourable?","volume":"23","author":"Sakkal","year":"2016","journal-title":"Current medicinal chemistry"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0022","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.3390\/ijms15069718","article-title":"Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma","volume":"15","author":"Zhang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/modpathol.2014.104","article-title":"Peritumoral eosinophils predict recurrence in colorectal cancer","volume":"28","author":"Harbaum","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0024","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","article-title":"Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors","volume":"95","author":"von Wasielewski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0046-8177(96)90216-6","article-title":"Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response","volume":"27","author":"van Driel","year":"1996","journal-title":"Human pathology"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040671","article-title":"The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation","volume":"13","author":"Rimini","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2022.10.010_bib0027","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922010131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922010131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:35:47Z","timestamp":1778614547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324922010131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1465324922010131"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.10.010","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}